Cite
Leishmania amazonensis from distinct clinical forms/hosts has polymorphisms in Lipophosphoglycans, displays variations in immunomodulatory properties and, susceptibility to antileishmanial drugs.
MLA
Rêgo, Felipe D., et al. “Leishmania Amazonensis from Distinct Clinical Forms/Hosts Has Polymorphisms in Lipophosphoglycans, Displays Variations in Immunomodulatory Properties and, Susceptibility to Antileishmanial Drugs.” Cell Biology International, vol. 46, no. 11, Nov. 2022, pp. 1947–58. EBSCOhost, https://doi.org/10.1002/cbin.11880.
APA
Rêgo, F. D., Cardoso, C. d. A., Moreira, P. O. L., Nogueira, P. M., Araújo, M. S., Borges, V. M., Laurenti, M. D., Bartholomeu, D. C., Reis, A. B., Monte, N. R. L. d., & Soares, R. P. (2022). Leishmania amazonensis from distinct clinical forms/hosts has polymorphisms in Lipophosphoglycans, displays variations in immunomodulatory properties and, susceptibility to antileishmanial drugs. Cell Biology International, 46(11), 1947–1958. https://doi.org/10.1002/cbin.11880
Chicago
Rêgo, Felipe D., Camila d. A. Cardoso, Paulo Otávio L. Moreira, Paula M. Nogueira, Márcio S. Araújo, Valéria Matos Borges, Márcia D. Laurenti, et al. 2022. “Leishmania Amazonensis from Distinct Clinical Forms/Hosts Has Polymorphisms in Lipophosphoglycans, Displays Variations in Immunomodulatory Properties and, Susceptibility to Antileishmanial Drugs.” Cell Biology International 46 (11): 1947–58. doi:10.1002/cbin.11880.